Steven Fletcher
Overview
Explore the profile of Steven Fletcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
1465
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Drennen B, Goodis C, Bowen N, Yu W, Vickers G, Wilder P, et al.
RSC Med Chem
. 2022 Sep;
13(8):963-969.
PMID: 36092148
Overexpression of the anti-apoptotic BCL-2 proteins is associated with the development and progression of a range of cancers. Venetoclax, an FDA-approved BCL-2 inhibitor, is fast becoming the standard-of-care for acute...
12.
Chan A, Goodis C, Pommier E, Fletcher S
RSC Med Chem
. 2022 Sep;
13(8):921-928.
PMID: 36092144
Protein-protein interactions (PPIs) are large, often featureless domains whose modulations by small-molecules are challenging. Whilst there are some notable successes, such as the BCL-2 inhibitor venetoclax, the requirement for larger...
13.
Fox Z, Fletcher S, Fraisse A, Aditya C, Sosa-Carrillo S, Petit J, et al.
Nat Commun
. 2022 Apr;
13(1):2199.
PMID: 35459274
Microscopy image analysis has recently made enormous progress both in terms of accuracy and speed thanks to machine learning methods and improved computational resources. This greatly facilitates the online adaptation...
14.
Shukla S, Fletcher S, Chauhan J, Chalfant V, Riveros C, Mackeyev Y, et al.
Cancer Gene Ther
. 2022 Apr;
29(11):1550-1557.
PMID: 35440696
The proto-oncogene cellular myelocytomatosis (c-Myc) is a transcription factor that is upregulated in several human cancers. Therapeutic targeting of c-Myc remains a challenge because of a disordered protein tertiary structure....
15.
Zhang Y, Truong B, Fahl S, Martinez E, Cai K, Al-Saleem E, et al.
Blood
. 2022 Apr;
140(4):359-373.
PMID: 35436326
Although Ras/mitogen-activated protein kinase (MAPK) signaling is activated in most human cancers, attempts to target this pathway using kinase-active site inhibitors have not typically led to durable clinical benefit. To...
16.
Kaneshita S, Kida T, Yoshioka M, Nishioka K, Raje M, Sakashita A, et al.
Pulm Pharmacol Ther
. 2021 Aug;
70:102057.
PMID: 34425215
Pulmonary fibrosis is a progressive disease with poor prognosis and limited therapeutic options. In this study, we evaluated the potential therapeutic effects of CG223, a novel inhibitor of bromodomain and...
17.
Zheleznyak A, Mixdorf M, Marsala L, Prior J, Yang X, Cui G, et al.
Theranostics
. 2021 Aug;
11(16):7735-7754.
PMID: 34335961
Multiple myeloma (MM) is a multifocal malignancy of bone marrow plasma cells, characterized by vicious cycles of remission and relapse that eventually culminate in death. The disease remains mostly incurable...
18.
Chan A, Fletcher S
RSC Med Chem
. 2021 May;
12(2):178-196.
PMID: 34046608
Multi-factorial diseases are illnesses that exploit multiple cellular processes, or stages within one process, and thus highly targeted therapies often succumb to the disease, losing efficacy as resistance sets in....
19.
Fontana F, Scott M, Allen J, Yang X, Cui G, Pan D, et al.
Clin Cancer Res
. 2020 Dec;
27(7):1974-1986.
PMID: 33355244
Purpose: In multiple myeloma, drug-resistant cells underlie relapse or progression following chemotherapy. Cell adhesion-mediated drug resistance (CAM-DR) is an established mechanism used by myeloma cells (MMC) to survive chemotherapy and...
20.
Martinez 3rd R, Huang W, Samadani R, Mackowiak B, Centola G, Chen L, et al.
J Pharmacol Exp Ther
. 2020 Oct;
376(1):84-97.
PMID: 33109619
Constitutively active extracellular signal-regulated kinase (ERK) 1/2 signaling promotes cancer cell proliferation and survival. We previously described a class of compounds containing a 1,1-dioxido-2,5-dihydrothiophen-3-yl 4-benzenesulfonate scaffold that targeted ERK2 substrate...